← Back to Search

Angiotensin Receptor Blocker

Losartan for Arthrofibrosis

Phase 4
Waitlist Available
Led By Joshua Rozell, MD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days post-surgery
Awards & highlights

Study Summary

This trial will test whether losartan can reduce scar tissue formation and improve range of motion following surgery.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days post-surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days post-surgery for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Post-Operative Range of Motion (ROM)
Post-Operative Rate of Manipulation under Anesthesia (MUA)

Side effects data

From 2021 Phase 4 trial • 227 Patients • NCT02188121
43%
Laboratory values outside normal range
23%
Psychiatric Hospitalization
6%
Medical Hospitalization
2%
Elevated creatine kinase level
1%
Muscle pain
1%
Hypotension
1%
Dehydration
1%
Leukemia
1%
Placed on Lithium while on Losartan
100%
80%
60%
40%
20%
0%
Study treatment Arm
Statin and/or Angiotensin Receptor Blocker
Usual Treatment

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Losartan GroupExperimental Treatment1 Intervention
Group II: Control GroupActive Control1 Intervention
No additional steps in management are required for the control arm of the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Losartan
2003
Completed Phase 4
~3000

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,367 Previous Clinical Trials
839,721 Total Patients Enrolled
Joshua Rozell, MDPrincipal InvestigatorNYU Langone Health
1 Previous Clinical Trials
240 Total Patients Enrolled

Media Library

Losartan (Angiotensin Receptor Blocker) Clinical Trial Eligibility Overview. Trial Name: NCT05157464 — Phase 4
Arthrofibrosis Research Study Groups: Losartan Group, Control Group
Arthrofibrosis Clinical Trial 2023: Losartan Highlights & Side Effects. Trial Name: NCT05157464 — Phase 4
Losartan (Angiotensin Receptor Blocker) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05157464 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any additional participants needed for this research endeavor?

"As reported by clinicaltrials.gov, this medical trial has not been actively seeking patients since its last update on August 5th 2022. Despite that fact, 33 other trials have opened their doors to participants since then."

Answered by AI

Has the United States Food and Drug Administration given its stamp of approval to Losartan?

"As Losartan has already obtained approval, its safety score comes in at a 3."

Answered by AI

Has Losartan been previously employed for scientific experiments?

"Currently, there are 30 trials into Losartan's medical efficacy active. Of these, two have advanced to the third and final stage of clinical trialing. Most studies take place in San Francisco, California; however a total 533 locations across the globe are participating in research on this drug."

Answered by AI

What health issues does Losartan typically address?

"Losartan has a multitude of applications, but is typically prescribed to tackle diabetic nephropathy. It can also help reduce left ventricular hypertrophy and proteinuria, as well as treat hypertensive disease."

Answered by AI

What is the total sample size of this experiment?

"Unfortunately, this trial has closed its recruitment period. The posting was first published on November 1st 2022 and the latest modifications were made on August 5th 2022. However, if you are still looking for studies to join, there are 3 trials that accept patients with arthrofibrosis and 30 more involving Losartan therapy currently open for enrolment."

Answered by AI

Who else is applying?

What state do they live in?
Louisiana
Washington
How old are they?
65+
What site did they apply to?
NYU Langone Health
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Losartan Use to Mitigate Arthrofibrosis Following Total Join Arthroplasty
2023. "Losartan Use to Mitigate Arthrofibrosis Following Total Join Arthroplasty". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05157464.
~0 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top